FDA Compliance for Peptide Therapy and BPC 157 Holt Law FDA Updates Safety Label for Capecitabine and 5 FU for Risks Associated With DPD Deficiency Oncology Nursing Society The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and